Please provide your email address to receive an email when new articles are posted on . Despite higher pain scores at 8 hours postoperatively and increased opioid use, local infiltration analgesia was ...

In both studies, Exparel achieved a statistically significant reduction in cumulative pain scores from 0 to 96 hours compared with bupivacaine hydrochloride. The Food and Drug Administration (FDA) has ...

Patients who received interscalene brachial plexus block plus soft tissue infiltration with Exparel when undergoing primary shoulder arthroplasty used significantly more narcotics postoperatively and ...

— EXPAREL is the only FDA-approved single-dose regional analgesic to safely demonstrate four days of superiority versus bupivacaine in two clinical studies — — New indications for use as an adductor ...

The Food and Drug Administration (FDA) has approved the use of Exparel (bupivacaine liposome injectable suspension; Pacira Pharmaceuticals) as an interscalene brachial plexus block to produce ...

Pacira Biosciences, Inc. (NASDAQ: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced it has joined the PROBE ...

Medically reviewed by Nicholas R. Metrus, MDMedically reviewed by Nicholas R. Metrus, MD A nerve block for migraine headaches involves an injection of a local anesthetic into the base of the skull or ...

When back pain won’t go away, your doctor will consider all the treatments that could help you, from exercise and physical therapy to medication. Part of that may include injections to ease your back ...